{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:52:23Z","timestamp":1793735543237,"version":"4.6.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40265-022-01765-5","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T09:03:37Z","timestamp":1661245417000},"page":"1419-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Vutrisiran: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"1765_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00683-z","author":"A Aimo","year":"2022","unstructured":"Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022. https:\/\/doi.org\/10.1038\/s41569-022-00683-z.","journal-title":"Nat Rev Cardiol"},{"key":"1765_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2052838","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022. https:\/\/doi.org\/10.1080\/13506129.2022.2052838.","journal-title":"Amyloid"},{"issue":"2","key":"1765_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1765_CR4","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.3390\/jcm11082148","volume":"11","author":"C Tsch\u00f6pe","year":"2022","unstructured":"Tsch\u00f6pe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges. J Clin Med. 2022;11(8):2148.","journal-title":"J Clin Med"},{"key":"1765_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323.","journal-title":"Ther Clin Risk Manag"},{"key":"1765_CR6","unstructured":"Alnylam Pharmaceuticals Inc. Hereditary ATTR amyloidosis; 2021. https:\/\/www.hattramyloidosis.com\/. Accessed 4 Jul 2022."},{"key":"1765_CR7","unstructured":"Alnylam Pharmaceuticals Inc. AMVUTTRA (vutrisiran): US prescribing information; 2022. https:\/\/www.amvuttra.com\/. Accessed 27 June 2022"},{"key":"1765_CR8","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam announces FDA approval of AMVUTTRA\u2122 (vutrisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults [media release]. 13 June 2022. https:\/\/investors.alnylam.com\/."},{"key":"1765_CR9","unstructured":"European Medicines Agency. Amvuttra (vutrisiran): Committee for Medicinal Products for Human Use (CHMP) summary of opinion; 2022. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-amvuttra_en.pdf. Accessed 28 Jul 2022."},{"key":"1765_CR10","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam receives positive CHMP opinion for vutrisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy [media release]. 22 Jul 2022. https:\/\/investors.alnylam.com\/."},{"key":"1765_CR11","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam announces new advances in ATTR amyloidosis program [media release]. 11 May 2021. http:\/\/www.alnylam.com."},{"key":"1765_CR12","doi-asserted-by":"crossref","unstructured":"Shilling R, Karsten V, Silliman N, et al. Study design and rationale of HELIOS-B: a phase 3 study to evaluate the clinical efficacy and safety of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy [abstract no. 1323\u2013359]. J Am Coll Cardiol. 2020;75(11 Suppl. 1):3579.","DOI":"10.1016\/S0735-1097(20)34206-6"},{"key":"1765_CR13","unstructured":"Blackstone Life Sciences. Blackstone and Alnylam close $150 million R&D financing to advance RNAi therapeutics for cardiovascular disease [media release]. 17 Aug 2020. http:\/\/www.blackstone.com."},{"key":"1765_CR14","unstructured":"Blackstone Life Sciences, Alnylam Pharmaceuticals Inc. Blackstone and Alnylam enter into $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics [media release]. 13 April 2020. http:\/\/www.blackstone.com."},{"key":"1765_CR15","unstructured":"Sanofi, Alnylam Pharmaceuticals Inc. Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance [media release]. 8 April 2019. http:\/\/www.sanofi.com."},{"key":"1765_CR16","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam and Sanofi enter into strategic restructuring of RNAi therapeutics rare disease alliance [media release]. 7 Jan 2018. https:\/\/investors.alnylam.com\/."},{"key":"1765_CR17","unstructured":"Genzyme, Alnylam Pharmaceuticals Inc. Genzyme and Alnylam expand collaboration on rare genetic diseases [media release]. 13 Jan 2014. http:\/\/www.genzyme.com."},{"key":"1765_CR18","unstructured":"Alnylam Pharmaceuticals Inc. Genzyme exercises its right to purchase additional shares of Alnylam common stock [media release]. 26 Mar 2014. http:\/\/www.alnylam.com."},{"key":"1765_CR19","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam announces closing of previously announced alliance with Genzyme for discovery, development, and commercialization of RNAi therapeutics as genetic medicines [media release]. 27 Feb 2014. http:\/\/www.alnylam.com."},{"key":"1765_CR20","unstructured":"Alnylam Pharmaceuticals Inc., Genzyme. Alnylam and Genzyme form alliance to develop and commercialize RNAi therapeutics in Asia [media release]. 22 Oct 2012. http:\/\/www.alnylam.com."},{"key":"1765_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985","author":"D Adams","year":"2022","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyrethrin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022. https:\/\/doi.org\/10.1080\/13506129.2022.2091985.","journal-title":"Amyloid"},{"key":"1765_CR22","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P., Gillmore J, Kale P, et al. HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis. In: Heart Failure 2022 and World Congress on Heart Failure; 2022.","DOI":"10.1016\/j.acvdsp.2022.10.056"},{"issue":"1","key":"1765_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01765-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01765-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01765-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T17:01:17Z","timestamp":1676480477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01765-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1765"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01765-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"5 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}